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Summary Microcolonies were obtained by culturing cells of two human osteosarcoma lines (OHS and
KPDX) and one human melanoma line (WIX-c) for either 24 or 72 h. The microcolonies were treated with
either a-particle radiation emitted by the 2"'At-labelled monoclonal antibody (MAb) TP-3 or external beam
X-rays. Survival of microcolonies was assayed by colony formation. Therapeutic gain factor (TGF) values
were calculated for two survival levels, 50% and 20% microcolony regeneration (i.e. at least one cell in 50%
or 20% of the colonies survived the treatments). The TGF values were affected by the specific activity of the
21'At-MAb conjugate, the antigen expression of the cells and the size and growth pattern of the microcolonies.
Treatment with 21'At-TP-3 gave TGF values that varied from 1.3 ± 0.4 to 4.5 ± 0.7 (mean ±s.e.). The
antigen-rich OHS cell line had on average 1.6 times higher TGF than the antigen-poor KPDX cell line. The
TGF increased significantly with colony size for the densely packed colonies of the KPDX cell line but not for
the OHS cell line, which had colonies with cells growing in a more scattered pattern. Control experiments with
the two non-specific 21'At forms, free 211At and 21'At-labelled bovine serum albumin, gave TGF values from
0.6 ± 0.1 to 1.0 ± 0.3. This study suggests that in vivo evaluation of 211At-MAbs using relevant tumour models
is desirable.
Compounds labelled with the a-particle emitter 2"'At have for
some time been preclinically investigated as a means for
irradiation of tumour cells (Bloomer et al., 1981; Brown et
al., 1981; Vaughan et al., 1981, 1982; Harrison & Royle,
1987; Link et al., 1989). Although therapeutic effects have
been achieved with compartmentally delivered non-specific
2"'At preparations in murine models (Bloomer et al., 1984;
Vergote et al., 1992), the use of 2"'At-labelled compounds
with some degree of selective tumour uptake seems to be the
most promising strategy (Humm, 1987; Humm & Chin,
1993). The therapeutic potential of a-emitters is increased
when they are coupled to molecules with high tumour affinity
because of the short range and high ionisation density of
a-particles (Brown, 1986; Kozak et al., 1986; Kurtzman et
al., 1988; Macklis et al., 1989).
We have recently studied the cytotoxicity of 2"At-TP-3
monoclonal antibody (MAb) on single-cell suspensions of
three human osteosarcoma cell lines (OHS, SAOS and
KPDX) (Larsen et al., 1994). The study showed that the
sensitivity to 2"1At-TP-3 treatment was governed by cellular
properties other than those governing sensitivity to treatment
with external beam X-rays. The cellular property most
important for sensitivity to 21 At-TP-3 was the antigen den-
sity. The cell inactivation was found to increase substantially
with increasing specific activity of the 21 At-TP-3 preparation.
At high specific activities, the cytotoxic effect of 2"1At-TP-3
was significantly higher than that of non-specific 21 At-
lab.elled bovine serum albumin (BSA). It was concluded that
21 At-TP-3 of high specific activity may have the potential to
give clinically favourable therapeutic ratios in the treatment
of osteosarcoma.
The clinical conditions for many types of cancer are nor-
mally very different from the conditions in the single-cell
suspension model. Osteosarcoma, for instance, has a strong
tendency to metastasise by cells being trapped in the bone
marrow sinusoids and lung capillaries. Cells in microcolonies
infiltrating or growing adjacent to normal tissue will have
binding kinetic conditions different from free-floating single
cells. Steric hindrance from adjacent cells may reduce the
number of antigens available for circulating MAbs and,
hence, reduce the potential of radioimmunotherapy (RIT).
On the other hand, radiation cross-fire from radiolabelled
antibody molecules bound to antigens of neighbouring cells
may enhance the efficacy of RIT against tumour cell col-
onies.
In the present paper we have extended our in vitro inves-
tigation of a-particle RIT from the single-cell suspension
model to a surface-deposited microcolony model. A surface-
deposited microcolony model was chosen rather than a mul-
ticellular spheroid model to avoid the large penetration bar-
rier for MAbs usually seen in spheroids. We used two human
osteosarcoma cell lines (OHS and KPDX) with very different
antigen expression, and one human malignant melanoma cell
line (WIX-c) with no significant antigen expression for the
sarcoma-associated MAb TP-3 (Bruland et al., 1986). Micro-
colonies were grown on a plastic surface in tissue culture
flasks. Inactivation was studied following treatment with
21 At-TP-3 MAb, free 2"'At, 21'At-BSA and external beam
X-rays. The objective of this study was to measure and
quantify the therapeutic gain from 21'At-labelled MAb on
antigen-positive versus antigen-negative microcolonies and to
determine some parameters important for RIT of tumour
micrometastases.
Materials and methods
Cell lines
The two human osteosarcoma cell lines, OHS and KPDX
(Bruland et al., 1985; Fodstad et al., 1986), and the human
melanoma cell line, WIX-c (Rofstad et al., 1991), have been
described in detail previously. WIX-c is more resistant to
X-rays than OHS and KPDX. The X-ray survival curve
parameters have been found to be: Do = 0.60 ± 0.03 Gy,
n=9.9±2.2 (OHS); D0=0.82±0.lOGy, n=3.7±1.2
(KPDX) (Larsen et al., 1994); and Do = 0.98 ± 0.04 Gy,
n = 2.9 ± 1.1 (WIX-c) (Rofstad, 1992).
The cell lines were cultured in monolayer in RPMI-1640
medium (25 mM HEPES and L-glutamine) supplemented with
13% fetal calf serum, 250 mg 1' penicillin and 50 mg 1'
streptomycin. The cells were incubated at 37°C in a humidi-
fied atmosphere of 5% carbon dioxide in air and subcultured
every 5-7 days after treatment with 0.05% trypsin/0.02%
EDTA. Cells in passages 50-100 in vitro were used in the
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present work. The cell lines were found to be free from
Mycoplasma contamination by using the Hoechst
fluorescence and the mycotrim methods.
Monoclonal antibody and antigen expression
The MAb TP-3 of subclass IgG2b, which recognises an
80 kDa antigen commonly expressed on sarcoma cells (Bru-
land et al., 1988), was used. Production and purification have
been described elsewhere (Bruland et al., 1986). The average
numbers of antigens per cell were 7.4 x 105 and 1.2 x 105 for
OHS and KPDX respectively (Larsen et al., 1994). WIX-c
had no significant antigen expression for TP-3.
Production of21'At
21'At (half-life 7.2 h) was produced by the 2'Bi(a,2n)2"1At
reaction at the cyclotron at Oslo University. After separation
from the bismuth target (Larsen et al., 1993), the astatine
was coupled to the MAb or BSA using the ATE method
(Zalutsky & Narula, 1987; Garg et al., 1989). The procedures
for astatine labelling of MAbs have been described in detail
elsewhere (Zalutsky et al., 1989). The immunoreactivities
were measured according to previously published procedures
(Lindmo et al., 1984) using OHS cells and were between 55%
and 75%. Solutions with free 2"'At were made by dissolving
elementary astatine in phosphate-buffered saline (pH 7.4).
Microcolonies
Cells in exponential growth were harvested by trypsinisation
and plated in various numbers in 25 cm2 tissue culture flasks
(Nunclon) containing 1 x 105 lethally irradiated (30Gy)
feeder cells, which were plated 24 h earlier. It was verified
experimentally that the feeder cells themselves did not give
rise to colonies and that the use of feeder cells increased and
stabilised the plating efficiency (PE). The cells were incubated
at 37°C in a humidified atmosphere of 5% carbon dioxide in
air for 24 or 72 h for formation of microcolonies. The size
and growth pattern of the microcolonies were examined by
light microscopy before irradiation. Three control flasks and
three flasks containing irradiated microcolonies were used to
determine each survival level in each experiment.
The number of cells in the microcolonies is presented in
Table I. The cells in the 24 h microcolonies were difficult to
count exactly because of difficulty in distinguishing viable
cells from clonogenically inactive feeder cells. However, a
maximum number of cells per colony was established.
External beam X-ray irradiation
X-ray irradiation was performed at a dose rate of
4.0 Gy min-' using a Muller RT 250 X-ray unit operated at
250 kV and 20 mA, and with 0.5 mm copper filtration of the
beam (Rofstad; 1992).
Incubation with 21'At preparations
After addition of 21'At preparations, the flasks were
incubated on a tilting platform for 90 min. The platform was
tilted carefully to avoid loss of cells from the surface-bound
microcolonies. The flasks were then placed in an incubator
and the 21At was allowed to decay completely. Activity levels
of 10, 25 and 50 kBq per ml of tissue culture medium (initial
activity) were used.
Table I Number of cells in microcolonies
Cell line 24 h microcolonies 72 h microcolonies
OHS 1-4 13.5 ± 0.7
KPDX 1-4 11.5 ± 0.6
WIX-c 1-4 12.1 ± 1.0
The cells were counted using a stereomicroscope. The values are
based on data from four individual experiments (72 h microcolony
values: mean ± s.e.).
Clonogenic assay
The cells were incubated for 1-3 weeks after the radiation
exposure. The culture medium was replaced approximately
once a week. The colonies were fixed in ethanol, stained with
methylene blue and counted using a stereomicroscope. The
surviving fraction (SF) of microcolonies was determined as
follows:
SF = (number of colonies after treatment)/
(number of colonies in untreated control)
Curvefitting, therapeutic gain calculations andstatistical
analysis
Survival curves were fitted to the data using linear dose-log
survival interpolation between experimental points. The doses
(medium activities) to give at least one surviving cell in 50%
[D50 (A5o)] and 20% [D20 (A)20)] of the microcolonies were
found by linear dose (medium activity)-log survival inter-
polation between two experimental points. Standard errors
(s.e.) were calculated from the s.e. of the two nearest experi-
mental points. Therapeutic gain factor (TGF) for 211At-TP-3
RIT relative to X-ray treatment was calculated according to
the equation (e.g. OHS, 50% colony survival):
TGF, = [D50 (X-rays, OHS)/A0(21At-TP-3, OHS)]/
[D50(X-rays, WIX-c)/A50(21 At-TP-3, WIX-c)]
i.e., the antigen positive osteosarcoma cell lines were used as
models for tumour tissue and the antigen-negative melanoma
cell line was used as model for normal tissue. TGF for
2"At-TP-3 RIT was also calculated according to the equation
(e.g., KPDX, 20% colony survival):
TGF20 = [A20(21At-BSA, KPDX)]/[A20(211At-TP-3, KPDX)]
i.e. the tumour tissue damage was modelled by the cell
inactivation caused by the 211At-TP-3 treatment and the nor-
mal tissue damage by the cell inactivation caused by the
21'AT-BSA treatment.
The TGF values were calculated using both 50% and 20%
survival of microcolonies. One-way analysis of variance fol-
lowed by a Student-Newman-Keuls test was used to iden-
tify differences between cell lines. A significance level of
P = 0.05 was used.
Results
X-ray irradiation
The external beam X-ray survival curves for microcolonies
are presented in Figure 1. The survival increased with micro-
colony size, in agreement with the increase in cell number per
microcolony and the PE of the single cells in the micro-
colonies. The WIX-c cell line was more resistant than the
OHS and KPDX cell lines (P<0.05), which had a similar
response to X-rays. The D50 and D20 values for X-ray irradia-
tion of microcolonies are presented in Table II.
21'AT-TP-3 MAb
The microcolony survival curves for OHS, KPDX and WIX-c
incubated with 21'At-TP-3 are shown in Figure 2. Figure 2a
presents the curves for 24 h microcolonies incubated with
21 At-TP-3 of 14 MBq mg-'. The curves for 24 h micro-
colonies exposed to 21 At-TP-3 of 50 MBqmg-' are shown in
Figure 2b. A comparison of Figure 2a and 2b shows that the
increase in specific activity resulted in reduced regeneration
of microcolonies for the OHS line, whereas the KPDX line
showed a significant difference only at the 50 kBq ml l
medium activity level. In Figure 2c the survival curves for
72 h microcolonies are presented. At the 10 kBq ml-' activity
level the difference between the survival of OHS and KPDX
was minor. At higher medium activities the OHS line was
affected considerably more than the KPDX line.1002 R.H. LARSEN et al.
10° The survival for both OHS and KPDX was clearly lower
than that for WIX-c at all activity levels. Aso and A20 values
for OHS, KPDX and WIX-c incubated with 21 At-TP-3 MAb
are presented in Table III. For the 24 h microcolonies
incubated with 2"At-TP-3 of 14 MBqmg-', OHS and KPDX
had similar A50 values. Otherwise, OHS had significantly
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Figure 1 OHS (0), KPDX (0) and WIX-c (-) microcolonies
irradiated with X-rays 24 h (a) or 72 h (b) after plating of single
cells on a plastic surface in tissue culture flasks. Survival fraction
points represent geometrical mean (± s.e.) calculated from 3-5
experiments.
Table II D50 and D20 values for external beam X-ray irradiation of
microcolonies
24 h microcolonies 72 h microcolonies
Cell line D50 (Gy) D20 (Gy) D50 (Gy) Dm (Gy)
OHS 1.5±0.1 3.0±0.4 1.6±0.2 3.6±0.5
KPDX 1.5±0.1 3.1 ±0.7 2.0±0.1 4.3±0.4
WIX-c 3.3 ± 0.2 4.9 ± 0.6 4.2 ± 0.5 6.0 ± 1.2
The dose (± s.e.) in Gy to give 50% (D50) and 20% (D20) survival
of microcolonies calculated using linear dose-log survival
interpolation between experimental points (Figure 1). s.e. values were
calculated from the s.e. values of the two nearest experimental
points.
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Figure 2 OHS (0), KPDX (0) and WIX-c (0) microcolonies
exposed to 2"At-TP-3 monoclonal antibody with a specific
activity of 14 MBq mg-' 24 h after plating (a), 50 MBq mg-1 24 h
after plating (b) and 50 MBq mg-' 72 h after plating (c) of single
cells on a plastic surface in tissue culture flasks. The activity was
allowed to decay completely. Survival fraction points represent
geometrical mean (± s.e.) calculated from 3-6 experiments.THERAPEUTIC GAIN WITH 2"At-LABELLED MAb 1003
lower A50 and A20 values than KPDX (P<0.05), and both
had significantly lower A50 and A20 values than WIX-c
(P<0.05). There was no significant change in survival of
24 h microcolonies of WIX-c caused by the increase in
specific activity from 14 MBq mg-' to 50 MBq mg-' of the
2"At-MAb.
21'At-BSA andfree 21'At
The microcolony survival curves for 2"'At-BSA and free 2"At
are presented in Figures 3 and 4. At activity levels of 25 and
50 kBqml-', free 2"'At was significantly more toxic than
2"'At-BSA (P<0.05). The curves for 24 h microcolonies of
WIX-c incubated with 2"At-BSA and 2"At-TP-3 are similar.
A50 and A20 values for the two forms are presented in Table
IV.
Therapeutic gainfactor
TGF values were calculated for the treatment of OHS and
KPDX microcolonies with 2"At-TP-3 MAb by using WIX-c
Table III A50 and A20 values for 2"At-TP-3 added to the culture
medium of microcolonies
(Table V) or treatment with 2"'At-BSA (Table VI) as
references. TGFm and TGF20 were consistently above unity
and were on average a factor of 1.6 larger for OHS than for
KPDX, and this agrees with the higher antigen expression of
the OHS cell line.
TGF values were also calculated for the non-specific 21'At
forms free 2"1At and 2"At-BSA for comparison (Table V).
There was no significant difference between the two osteosar-
coma cell lines. The values were varying from 0.6±0.1 to
1.0 ± 0.3 (mean ± s.e.) and there was no significant difference
between free 2"At and 2"'At-BSA.
Discussion
Therapeutic gain measured in vitro reflects to a large extent
the experimental conditions. It is noteworthy that the experi-
mental procedures used here did not allow any strong mixing
of the cells and the 2"At-MAb preparations, and that the
unbound 2"At preparations were allowed to d6cay complete-
ly in the growth medium, giving a high non-specific dose to
the cells. Nevertheless, significant therapeutic gain was
achieved with 2"At-TP-3 on antigen-positive cells. The
parameter most strongly influencing the therapeutic gain was
the specific activity of the 2"At-MAb preparation. Owing to
Cell line OHS KPDX WIX-c
24 h microcolonies
14MBqmg-'
A50 5.2 ± 0.9 5.8 ± 0.7 28.4 ± 1.0
A20 15.7±3.1 24.6±0.7 49.6±9.1
50 MBq mg-'
A50 3.3 0.3 6.8 0.5 25.9 1.0
A20 7.7 1.1 20.1 3.9 46.9 6.8
72 h microcolonies
50 MBq mg-'
A50 6.0 0.7 8.0 0.6 46.3 ± 3.7
A20 14.5 1.5 28.4 3.1 a
Added activity (± s.e.) in kBq ml-' in the culture medium to give
50% (A50) and 20% (A20) survival of microcolonies calculated using
linear activity-log survival interpolation between experimental
points (Figure 2). The 21 preparations were allowed to decay
completely (>72 h) before the medium was changed. s.e. values were
calculated from the s.e. values of the two nearest experimental
points. aThe 20% survival level was outside the region covered by
experimental data for WIX-c.
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Figure 3 OHS (0), KPDX (0) and WIX-c (-) microcolonies
exposed to 21'At-BSA 24 h after plating of single cells on plastic
surface in tissue culture flasks. The activity was allowed to decay
completely. Survival fraction points represent geometrical mean
(± s.e.) calculated from six experiments.
Figure 4 OHS (0), KPDX (0) and WIX-c (a) microcolonies
exposed to free 2"At 24 h after plating of single cells on plastic
surface in tissue culture flasks. The activity was allowed to decay
completely. Survival fraction points represent geometrical mean
(± s.e.) calculated from six experiments.
Table IV A50 and A20 values for 21"At and 2"At-BSA added to the
culture medium of microcolonies
Cell line OHS KPDX WIX-c
24 h microcolonies
Free 2"At
A50 12.4± 1.0 10.2± 1.0 15.4± 1.9
A20 22.3 ± 3.1 17.3 + 2.5 26.4 + 6.9
21'At-BSA
Amo 15.0 1.8 15.5 0.9 26.8 2.1
A20 32.7 ± 15.9 32.8 ± 3.1 48.3 + 12.6
Added activity (± s.e.) in kBqml-' in the culture medium to give
50% (A50) and 20% (A20) survival of microcolonies calculated using
linear activity-log survival interpolation between experimental
points (Figures 3 and 4). The 21At preparations were allowed to
decay completely (>72 h) before the medium was changed. s.e.
values were calculated from the s.e. values of the two nearest
experimental points.
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Table V Therapeutic gain factors
Cell line OHSIWIX-c KPDX/WIX-c
24 h microcolonies
Free 2"At
TGF50 0.6±0.1 0.7±0.1
TGF20 0.7 ± 0.3 1.0 + 0.3
21"At-BSA
TGF50 0.8±0.2 0.8±0.1
TGF20 0.9 0.3 1.0 0.3
24 h microcolonies
14 MBq mg'l 21'At-TP-3
TGF50 2.5 ± 0.5 2.3 ± 0.3
TGF20 2.0 0.6 1.3 0.4
50 MGq ' 21At-TP-3
TGF50 3.7±0.5 1.8 0.2
TGF20 3.8 1.0 1.5±0.3
72 h microcolonies
50 MBq mg-' 211At-TP-3 2.9 ± 0.6 2.7 ± 0.4
The therapeutic gain factors for 50% (TGF50) and 20% (TGF20)
microcolonies survival. TGF (± s.e.) was calculated according to the
following equation (e.g. TGF50, OHS, 21'At-BSA):
TGF = [D50 (OHS, X-rays)/A50 (OHS, 211At-BSA)]/[D50 (WIX-c,
X-rays)/A50 (WIX_c, 21"At-BSA)].
Table VI Therapeutic gain factors for 211At-TP-3 vs 21'At-BSA
Cell line OHS KPDX WIX-c
14 MBq mg'
TGF50 2.9 ± 0.6 2.7 ± 0.4 0.9 ± 0.1
TGF20 2.1±0.6 1.3±0.3 1.0±0.3
50MBqmg'
TGF5n 4.5±0.7 2.3±0.2 1.0±0.1
TGF20 4.2± 1.0 1.6±0.3 1.0±0.3
The therpeutic gain factors were determined for 50% (TGF5o) and
20% (TGF20) survival of 24 h microcolonies. TGF (± s.e.) was
calculated according to the following equation (e.g. OHS):
TGF = [A50 (OHS, 211At-BSA)/A5n (OHS, 211At-TP-3)J.
the short range of the a-particles (<80 gm) the radiation
dose to the target cells mainly comes from cell-bound 21 At-
MAbs. The dose is therefore under ideal conditions (i.e. all
target cells contain antigens to the MAb) proportionally
dependent on the number of 21'At bound to the cells. At
antigen saturation, this number is proportional to the specific
activity of the MAb. Optimisation of immunoreactivity,
specific activity of 21 At-MAb and clearance of non-bound
211At-MAb will therefore increase the therapeutic gain fur-
ther.
The therapeutic gain was in this study measured in two
ways. Firstly, TGF values were determined for the antigen-
positive cell lines using the antigen-negative cell line as
reference. In this case corrections for differences in X-ray
sensitivity were included. Secondly, TGF values were deter-
mined by comparison of the cytotoxicity of the cell-binding
211At-MAb with that of a non-specific 21'At-protein using the
same cell line. The target tissue (OHS and KPDX osteosar-
coma microcolonies) was more sensitive to X-rays than the
control tissue (WIX-c melanoma microcolonies). A system
with resistant tumour cells and sensitive control cells would
have given higher therapeutic gain. This is because cell lines
generally show less variability in radiation response when
treated with high linear energy transfer (LET) radiation, e.g.
a-particles and slow neutrons, than when treated with low-
LET radiation (Hall, 1988).
A characteristic that may be important for the therapeutic
gain of a-particle RIT is the growth pattern of the cells
within a microcolony. Microscopical examinations revealed
that the OHS cells tended to grow in a scattered pattern
while the KPDX cells tended to grow tightly in the micro-
colonies. The a-particle intra-colony cross-fire was therefore
more important for the KPDX than for the OHS micro-
colonies. This explains why the 72 h microcolonies had
significantly higher TGF values than the 24 h microcolonies
for KPDX-but not for OHS.
The experiments with 2"'At-BSA and 21 At-TP-3 on the
antigen-free WIX-c cell line show that the change in
molecular size from approximate molecular weight (MW) of
66,000 to approximate MW of 160,000 did not influence the
cytotoxicity of the 21'At-protein conjugate. Moreover a
change in the specific activity of 21 At-TP-3 from 14 to
50MBqmg-' did not change the non-specific cytotoxicity
against WIX-c microcolonies significantly. It can therefore be
concluded that the cytotoxicity of non-specific 21'At-labelled
proteins is not significantly influenced by the size and the
specific activity of the 21'At-protein conjugate.
The uptake of radiolabelled MAbs measured in tumours in
patients has generally been low (Epenetos et al., 1986).
Clinically, intravenously injected short-lived ax-particle-
emitting radioimmunoconjugates such as 21 At-TP-3 cannot
be expected to give substantial therapeutic gain in the treat-
ment of large solid tumours. The in vitro study presented
here indicates, however, that a well-vascularised tumour or
micrometastases may be candidates for treatment with 21 At-
MAbs, on the conditions that the MAb binds strongly to the
tumour cells and has a low cross-reactivity with normal
tissue. Further in vivo studies with relevant tumour models
are therefore desirable.
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